Amphastar Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - AMPH
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Amphastar Pharmaceuticals, Inc. for potential securities fraud. The investigation follows a secondary complete response letter from the FDA regarding Amphastar's generic teriparatide ANDA, AMP-015, after delays in submission.
March 04, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amphastar Pharmaceuticals is under investigation for potential securities fraud following an FDA secondary CRL for its generic teriparatide ANDA, AMP-015. This could negatively impact investor confidence and stock price.
The investigation by Levi & Korsinsky into potential securities fraud is significant as it follows an FDA secondary CRL, which indicates regulatory challenges. This could lead to decreased investor confidence and a potential drop in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100